Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05420909

A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer (mCRC) Clinical Trial

Official title:
Overall Survival for Metastatic Colorectal Cancer Patients Matched to CHECKMATE-142

Clinical Trial Summary

The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05420909
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase
Start date January 28, 2019
Completion date April 1, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02069704 - Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Phase 1
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. Phase 1
Completed NCT00594984 - Phase I/II Combination With Irinotecan- Erbitux Phase 1/Phase 2
Recruiting NCT03829462 - Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients Phase 3
Recruiting NCT04856787 - A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC Phase 2/Phase 3
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Not yet recruiting NCT06089330 - A Study of JMT101 in Patients With Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Active, not recruiting NCT03511963 - A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC Phase 3
Active, not recruiting NCT05839951 - An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions